Thursday July 02, 2020
  • |Subscribe
  • |Contribute
  • |About
  • |Access Your Account
  • |Register
  • |Login
  • |Home
  • |Current Issue
  • |Issue Archive
    • |Featured Reports
    • |eBooks
  • |BioProcess Insider
  • |Multimedia
    • |BPI White Papers
    • |Webinars
    • |Posters
  • |BioProcess International Events
    • |BioProcess International Europe
    • |BioProcess International US West
  • |BioProcess International Academy
  • |Events

BioProcess International

Covering the whole development process for the global biotechnology industry

  • Upstream
    Processing
    Bioprocessing begins upstream, most often with culturing of animal or microbial cells in a range of vessel types (such as bags or stirred tanks) using different controlled feeding, aerating, and process strategies.
    • Assays
    • Biochemicals/Raw Materials
    • Bioreactors
    • Cell Culture Media
    • Expression Platforms
    • Fermentation
    • Perfusion Cell Culture
    • Upstream Contract Services
    • Upstream Single-Use Technologies
  • Downstream
    Processing
    Beginning with harvest of material from a bioreactor, downstream processing removes or reduces contaminants to acceptable levels through several steps that typically include centrifugation, filtration, and/or chromatographic technologies.
    • Filtration
    • Separation/Purification
    • Viral Clearance
    • Chromatography
    • Downstream Contract Services
    • Downstream Single-Use Technologies
  • Manufacturing
    Drug products combine active pharmaceutical ingredients with excipients in a final formulation for delivery to patients in liquid or lyophilized (freeze-dried) packaged forms — with the latter requiring reconstitution in the clinical setting.
    • Personalized Medicine
    • Single Use
    • Supply Chain
    • Vaccines
    • MAb
    • Biosimilars
    • Cell/Gene Therapies
    • Emerging Therapeutics
    • Facility Design/Engineering
    • Continuous Bioprocessing
    • Fill/Finish
    • Formulation
    • Information Technology
    • Manufacturing Contract Services
    • Process Monitoring and Controls
  • Analytical
    Many technologies are used to characterize biological products, manufacturing processes, and raw materials. The number of options and applications is growing every day — with quality by design (QbD) giving impetus to this expansion.
    • Culture Development
    • Cell Line Development
    • Downstream Development
    • Downstream Validation
    • Laboratory Equipment
    • PAT
    • Pre-Formulation
    • Product Characterization
    • QA/QC
    • Upstream Development
    • Upstream Validation
    • Leachables/Extractables/Particulates
  • Business
    Even as it matures, the biopharmaceutical industry is still a highly entrepreneurial one. Partnerships of many kinds — from outsourcing to licensing agreements to consultancies — help companies navigate this increasingly global business environment.
    • Careers
    • CMC Forums
    • Economics
    • Intellectual Property
    • Pre-Clinical and Clinical Trials
    • Regulatory Affairs
    • Risk Management
    • BioRegions

A New Generation of Generic HCP Assays

by BPI Contributor Monday, May 5, 2014  9:01 am

A New Generation of Generic HCP Assays

← Older Post

Editor’s Choice

  • BioProcess Insider

    CHO over? Biopharma and MIT team on alternative cell line R&D

  • BioProcess Insider

    Nex-T up: Bristol-Myers using machine learning to optimize future CAR-T

  • Sponsored Content

    Early Stage Analytical Considerations for Late-Stage Biologics Success

  • BioProcess Insider

    Inhouse and out: AstraZeneca secures COVID-19 vaccine capacity

  • BioProcess Insider

    Spark on changing cell and gene regulatory expectations

  • Sponsored Content

    Protein or Not? Advanced High-Throughput Aggregate Analysis with the Aura™

BioProcess Insider News and Analysis

Recent Tweets

  • Tweet Avatar RT @Dan5tanton: Manufacturing for #COVID19 vaccine to go to ‘Warp Speed’ https://t.co/kRYuE3Zi4H https://t.co/k1yY3wMweb 1 week ago
  • Tweet Avatar RT @Dan5tanton: Pharma Partnering: Perspectives from Xcelerating Life Sciences Panel https://t.co/TSX4cQrh3j via @xconomy 2 weeks ago
  • Tweet Avatar RT @Dan5tanton: Poll responses from @Xconomy #XconPHL How likely is it that viral vectors will remain the standard vehicle for th… https://t.co/Hj10ZT6vui 3 weeks ago
  • Tweet Avatar RT @Dan5tanton: #CDMO AGC Biologics expands again, buying a mothballed commercial-scale manufacturing facility in Boulder,… https://t.co/wz8g6HUuHd 4 weeks ago
Follow @bioproinsider

Trending

  • BioProcess Insider

    Mesoblast planning capacity hike if GVHD candidate is effective against COVID-19

  • BioProcess Insider

    Inhouse and out: AstraZeneca secures COVID-19 vaccine capacity

  • BioProcess Insider

    COVID-19 vaccine: A $14bn opportunity for bioprocess vendors

  • BioProcess Insider

    CHO over? Biopharma and MIT team on alternative cell line R&D

Explore Topics

  • Upstream Processing
  • Downstream Processing
  • Manufacturing
  • Analytical
  • Business

Publication

  • Issue Archive
  • Featured Reports
  • eBooks
  • Subscribe
Connect
Privacy policy

BioProcessIntl.com

  • White Papers
  • Posters
  • Webinars
  • BPI Theater
  • Awards
  • Register
  • Login
  • Access Your Account

Keep up with BPI

  • Email Newsletters
  • Events
  • BioProcess Insider
  • Twitter
  • LinkedIn

About BPI

  • Who We Are
  • Editorial Advisors
  • Author Guidelines
  • Advertising/Media Kit
  • List Rental/Reprints
  • Contact Us
  • Careers
BPI
twitter linkedin
Site Map|Contact
©2020 BioProcess International All Rights reserved
  • Home
  • Current Issue
  • Issue Archive
    â–¼
    • Featured Reports
    • eBooks
  • BioProcess Insider
  • Multimedia
    â–¼
    • BPI White Papers
    • Webinars
    • Posters
  • BioProcess International Events
    â–¼
    • BioProcess International Europe
    • BioProcess International US West
  • BioProcess International Academy
  • Events